Lithium for Seizures: Does It Help or Cause Them?

Lithium can both provoke and prevent seizures, depending on the dose, the duration of exposure, and the individual. At therapeutic blood levels used for bipolar disorder, seizures are uncommon but documented. At toxic levels, seizures become a recognized and sometimes dangerous complication. Yet a separate body of animal research shows that lithium, given acutely, can raise the threshold for chemically induced seizures. This contradiction has puzzled researchers for decades, and the exact mechanisms behind either effect remain incompletely understood.¹

When Lithium Triggers Seizures

The most straightforward path from lithium to seizures runs through toxicity. Lithium has an unusually narrow therapeutic window. The blood level considered effective for mood stabilization sits close to the level that causes harm, and small changes in kidney function, hydration, or interacting medications can tip a person from therapeutic range into toxicity. When lithium accumulates to dangerous levels, neurotoxicity is the most common consequence, and seizures are part of that picture.

A rat study examining different patterns of lithium poisoning found that the type of exposure mattered enormously. Animals given a single acute overdose developed brain dysfunction that peaked within hours and resolved within a day, and none of them seized. Animals poisoned in an acute-on-chronic pattern, mimicking someone on long-term lithium who then takes too much, developed more persistent brain dysfunction, and about one in five had seizures. The worst outcomes appeared in the chronic poisoning group, where brain dysfunction was severe and life-threatening, and over half developed seizures.² This pattern aligns with what clinicians see in humans: people on long-term lithium who gradually accumulate toxic levels tend to fare worse neurologically than those who take a single large dose without prior exposure.

A systematic review of lithium toxicity cases in older adults found that neurotoxicity was the most frequent manifestation, followed by kidney and heart problems. The average toxic blood level in those cases was roughly two and a half times the upper limit of the normal therapeutic range. Most of the affected patients had multiple other medical conditions and were taking several other medications, both of which increase the risk of lithium accumulating to harmful levels.³

Seizures That Do Not Look Like Seizures

One of the trickier complications of lithium toxicity is non-convulsive status epilepticus, a state of ongoing seizure activity in the brain that does not produce the dramatic shaking most people associate with seizures. Instead, the person may appear confused, disoriented, or slow to respond. Because lithium toxicity itself causes similar symptoms through direct chemical effects on brain cells, distinguishing between the two without an EEG recording is genuinely difficult.

A case report described a patient with bipolar disorder on therapeutic-range lithium who developed confusion and disorientation without any laboratory signs of toxicity. Her lithium blood level was normal. An EEG revealed continuous abnormal electrical activity consistent with non-convulsive status epilepticus. When she was given an anti-seizure medication intravenously, both the EEG pattern and her confusion resolved immediately. When lithium was later restarted, the same symptoms and EEG abnormalities returned, confirming lithium as the trigger. The authors concluded that even at normal therapeutic blood levels, lithium can provoke non-convulsive status epilepticus in people who are susceptible.⁴

A more recent case involved a patient whose initial convulsions were controlled with medication, but a simplified bedside EEG placed by emergency physicians revealed that seizure activity was continuing silently in the brain. Even after the visible seizures stopped, recurrent non-convulsive status epilepticus kept firing beneath the surface.⁵ This is a meaningful clinical problem because non-convulsive seizures that go unrecognized and untreated can cause lasting brain injury.

The diagnostic confusion runs deep. One review noted that lithium toxicity can produce confusional states through at least three distinct pathways: direct chemical toxicity to brain tissue, precipitation of non-convulsive status epilepticus, or interactions with other psychiatric medications that create dangerous overlap syndromes. These conditions look alike at the bedside, and the EEG patterns themselves can be ambiguous. Rhythmic slow waves and sharp discharges seen on EEG during lithium toxicity may represent true seizure activity or may reflect a toxic encephalopathy that mimics seizures electrically without being one.⁶

EEG Changes During Lithium Toxicity

Even when frank seizures do not occur, lithium toxicity frequently produces alarming patterns on brain wave recordings. A case report of an elderly woman with severe lithium intoxication documented periodic sharp wave complexes on EEG, a pattern that in other clinical contexts might raise concern for conditions as serious as prion disease.⁷ Another report described a bipolar disorder patient whose lithium toxicity produced both neurological symptoms and distinct abnormal EEG changes that tracked with blood lithium levels.⁸

These EEG findings matter practically because they can either prompt unnecessary panic or, worse, get dismissed as “just lithium toxicity” when the person is actually seizing. The takeaway for anyone involved in the care of a lithium-treated patient who becomes confused is that EEG monitoring is not optional. It changes management in real time.

Evidence That Lithium Can Prevent Seizures

Against this backdrop of seizure-provoking toxicity, a separate line of research shows lithium raising seizure thresholds in animal models. When mice were given a single dose of lithium and then challenged with a chemical that reliably triggers clonic seizures, the lithium-treated animals required significantly more of the chemical to seize than untreated ones. The effective doses of lithium ranged from 5 to 100 mg/kg, and the protective effect appeared to involve calcium signaling pathways and a specific type of brain receptor involved in excitatory transmission.⁹

How lithium achieves this is still being worked out. Research on lithium’s neuroprotective properties, primarily in the context of Alzheimer’s disease rather than epilepsy, has identified several mechanisms that could theoretically dampen seizure activity. At lower-than-therapeutic doses, lithium inhibits a key enzyme called GSK-3β, activates growth-promoting pathways in brain cells, supports the energy-producing structures inside neurons, and modulates the balance of inflammatory signals in brain tissue.¹⁰ All of these actions could plausibly contribute to making neurons less likely to fire uncontrollably, though translating this from petri dishes and mouse brains to human epilepsy remains a large leap.

The paradox is real but partly explained by context. Acute lithium at moderate doses appears to have a stabilizing effect on neuronal excitability. Chronic lithium accumulation to toxic levels overwhelms those stabilizing mechanisms and damages neurons directly, tipping the balance toward seizures. A molecule that subtly modulates brain chemistry at one concentration and poisons it at another is not as contradictory as it first appears; it is the dose and the duration that determine which face of lithium you see.

Lithium as a Research Tool for Inducing Seizures

Ironically, one of the most widely used laboratory methods for studying epilepsy depends on lithium’s ability to promote seizures. The lithium-pilocarpine model involves pretreating rats with a small dose of lithium chloride and then administering pilocarpine, a drug that stimulates a particular type of brain receptor. Neither drug at the doses used would reliably cause full-blown seizures on its own, but the combination consistently produces generalized convulsive status epilepticus, a prolonged state of continuous seizure activity.¹¹

This model has been used for decades to study what happens inside the brain during and after prolonged seizures. Research using this approach has shown that the resulting status epilepticus causes a surge in certain fats within brain tissue and weakens key antioxidant defenses in regions like the hippocampus, frontal cortex, and cerebellum, all of which help explain the brain damage that follows prolonged seizure activity.¹² The model is valuable precisely because it so reliably produces severe seizures, which underscores how potent lithium’s seizure-facilitating properties can be under the right circumstances.

The existence of this model sometimes confuses people into thinking lithium alone causes seizures easily. It does not. The lithium-pilocarpine effect depends on the two drugs interacting through overlapping brain pathways. Lithium alone, at the doses used in these experiments, does not cause seizures in the animals.

Treating Bipolar Disorder When Epilepsy Is Also Present

A practical question for patients and clinicians is what to do when someone has both bipolar disorder and epilepsy. Several mood stabilizers, including valproate and lamotrigine, are themselves anti-seizure medications, making them natural choices for people with both conditions. A nationwide population-based study examined outcomes in patients with comorbid bipolar disorder and epilepsy and concluded that valproate and lamotrigine should be prioritized in this group. The study also stressed the need for close clinical monitoring and psychological support, reflecting the complexity of managing two brain conditions simultaneously.¹³

Lithium is not absolutely ruled out in people with epilepsy, but it requires careful weighing. The main concern is not that therapeutic-level lithium will reliably worsen seizures, but that the margin for error shrinks. A person with epilepsy who develops even mild lithium toxicity from dehydration or a medication interaction faces a higher baseline risk of seizure complications than someone without epilepsy would. And because some epilepsy medications affect kidney function or electrolyte balance, drug interactions add another layer of complexity.

When the Damage Does Not Reverse

Most lithium toxicity, caught early, resolves once the drug is cleared from the body. But a subset of patients develop lasting neurological damage known as the Syndrome of Irreversible Lithium-Effectuated Neurotoxicity, or SILENT. This syndrome is defined by persistent neurological problems lasting at least two months after lithium is stopped, and it was first described in the late 1980s.¹⁴

A scoping review of reported SILENT cases found that the cerebellum, the brain region responsible for coordination and balance, bore the brunt of the damage in about three-quarters of cases. Other lasting problems included cognitive decline or dementia in roughly one in five patients, movement disorders resembling Parkinson’s disease in about one in six, and involuntary writhing movements in about one in ten. Many patients had multiple types of damage simultaneously.¹⁵ Brain imaging in affected patients typically shows scarring and shrinkage of the cerebellum along with other structural changes.¹⁶

SILENT is considered preventable. It nearly always follows a period of recognized lithium toxicity that was either treated too slowly or not recognized at all. The cases in the literature tend to involve older adults, patients with impaired kidney function, and situations where early warning signs of toxicity were missed or attributed to other causes. The name itself is something of a clinical plea: the syndrome is silent in onset but devastating in outcome, and earlier intervention could prevent most cases.

Lithium and Electroconvulsive Therapy

Another situation where lithium’s seizure-related properties become clinically relevant is electroconvulsive therapy. ECT works by intentionally inducing a brief, controlled seizure in the brain, and for some patients with severe depression or mania, it is highly effective. When a patient receiving ECT is also taking lithium, the combination has been associated with prolonged seizures during the procedure, along with increased risk of neurotoxicity and cognitive side effects.¹⁷ Many psychiatrists either reduce or temporarily hold lithium before an ECT course, though practice varies and the evidence base for the safest approach is limited.

How Lithium Toxicity Gets Treated

When lithium reaches dangerous levels and the patient is symptomatic, especially with neurological signs like confusion, decreased consciousness, or seizures, the priority is removing lithium from the body faster than the kidneys can manage on their own. Extracorporeal treatments, meaning blood-cleansing methods performed by a machine, are the mainstay.

Expert recommendations from a systematic review by a workgroup dedicated to extracorporeal treatment of poisonings state that dialysis is recommended when kidney function is impaired and the lithium level exceeds a certain high threshold, or when the patient has a decreased level of consciousness, seizures, or dangerous heart rhythm problems regardless of the blood level. Hemodialysis is the preferred method, though continuous kidney replacement therapy is an acceptable alternative.¹⁸

Standard hemodialysis clears lithium rapidly but has a practical catch: after the session ends, lithium that was stored inside cells redistributes into the bloodstream, causing a rebound in blood levels. This is why some centers opt for continuous dialysis methods, which remove lithium more slowly but steadily, minimizing that rebound effect and keeping blood pressure more stable, which matters in patients who are already medically fragile.³

Who Is Most Vulnerable

Older adults face disproportionate risk from lithium toxicity for straightforward physiological reasons. Kidney function declines with age, and lithium is cleared almost entirely by the kidneys. A dose that was safe at age 40 may become toxic at age 70 if kidney function has quietly deteriorated. The systematic review of lithium toxicity cases in older adults found an average age of about 71, with most patients on moderate lithium doses that would be unremarkable in a younger person. Over three-quarters had other medical conditions, and nearly two-thirds were taking multiple other medications, both of which can impair the body’s ability to handle lithium safely.

Dehydration is another common precipitant. Anything that reduces fluid volume, from a stomach virus to a heat wave to a new blood pressure medication that increases urination, can concentrate lithium in the blood. Patients on long-term lithium are typically advised to maintain consistent fluid and salt intake, but in practice, life gets in the way. A few days of poor oral intake during an illness is one of the most common triggers for lithium toxicity in clinical experience.

Kidney disease at any age also raises risk. Because lithium relies on the kidneys for clearance, even mild kidney impairment can tip blood levels upward. Complicating this, long-term lithium use itself can gradually impair kidney function, creating a feedback loop where the drug slowly undermines its own safe elimination. Regular blood monitoring of both lithium levels and kidney function is standard practice for anyone on the drug, but lapses in monitoring are common and consequences can be severe.

Why the Same Molecule Goes Both Ways

The fact that lithium can both raise and lower seizure thresholds is less paradoxical when you consider how broadly it affects brain chemistry. Lithium influences dozens of signaling pathways inside neurons, from the way cells handle calcium to the enzymes that regulate how excitable a nerve cell becomes. At moderate concentrations, the net effect of all these subtle tweaks appears to favor stability, nudging overactive circuits back toward baseline. This is presumably why it works as a mood stabilizer, dampening the extreme swings of bipolar disorder.

At toxic concentrations, that gentle modulation becomes a sledgehammer. Cellular energy production falters, protective antioxidant systems are overwhelmed, and the delicate balance of excitatory and inhibitory signaling tips toward chaos. Neurons in the cerebellum and hippocampus appear especially vulnerable. The shift from anticonvulsant to proconvulsant is not a switch being flipped but a threshold being crossed, and that threshold varies from person to person based on age, genetics, kidney function, hydration, and what other medications are on board.

Researchers are still working to untangle which specific molecular pathways matter most for each of lithium’s neurological effects. The hope is that understanding these mechanisms could eventually allow clinicians to retain lithium’s mood-stabilizing benefits while minimizing its neurological risks, or even to develop new seizure treatments inspired by the pathways lithium engages at protective doses. For now, the clinical reality is more straightforward: lithium remains one of the most effective treatments for bipolar disorder, its neurological risks are real but manageable with careful monitoring, and seizures in the context of lithium use are almost always a signal that something has gone wrong with dosing or clearance rather than an inherent property of the drug at therapeutic levels.